Arizona/Duke Clinical Center for AsthmaNet

亚利桑那/杜克哮喘临床中心

• 批准号: 8309312
• 负责人: Monica Kraft
• 金额: $ 86.26万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8309312
• 关键词: Acute; Address; Adult; Adult asthma; Alanine; Area; Arizona; Asthma; Authorization documentation; Azithromycin; Biological; Bronchoscopy; Budgets; Charge; Child; Childhood Asthma; Clinical; Clinical Management; Clinical Research; Clinical Trials; Collaborations; Collection; Comorbidity; Conflict (Psychology); DNA; Data; Development; Disease; Distant; Doctor of Medicine; Ensure; Environment; Funding; Genetic; Genetic Polymorphism; Genomics; Genotype; Hypersensitivity; IL8 gene; Institution; Journals; Lead; Leadership; Location; Lung; Medicine; Methods; Molecular and Cellular Biology; Mucous body substance; National Heart, Lung, and Blood Institute; Natural Immunity; New England; Obesity; Outcome; Participant; Patient Recruitments; Patients; Peptides; Periodicity; Persons; Pharmacogenetics; Pharmacotherapy; Phosphotransferases; Population; Preventive; Problem Solving; Production; Program Research Project Grants; Protocols documentation; Publishing; Randomized; Recruitment Activity; Relative (related person); Research; Research Personnel; Resolution; Resources; Respiratory Center; Retrieval; Risk; Role; Sampling; Schedule; Secure; Severities; Site; Solutions; Steroid Resistance; Subgroup; Symptoms; Telephone; Testing; Therapeutic; Time; Training; Tumor Necrosis Factor-alpha; Universities; Work; Writing; base; conflict resolution; cost; design; experience; forest; human TNF protein; improved; interest; meetings; novel; operation; organizational structure; prevent; programs; safety study; skills; success; symposium

Two Clinical management trial protocol proposals are included in The Duke/University of Arizona AsthmaNet Center. The adult asthma management trial will assess the role of TNF-alpha antagonists in improving asthma control in obese subjects who remain on control after optimization of pharmacotherapy and treatment of co-morbidities. The pediatric asthma management trial will test the hypothesis that azithromycin, a macrolyte, can be used at the first symptoms of acute asthma exacerbation to prevent such exacerbations, and if this preventive effect is specific for carriers of a genotype in a polymorphism in IL8 (IL8/-159 AA), which we have shown is associated with increased risk of neutrophilic exacerbations. We also propose two brief concept proposals: one in which we will test for the presence of steroid resistance in obese asthmatic subjects, and a second one in which we will determine the effect of myrisolated alanine-rich kinase substrate (MARCKS)-related peptide, which is a potential regulator of mucus secretion, in improving asthma control. Finally, we propose a clinical research skills development core plan that will use the many clinical, genetic and biological and training resources available in both our clinical research units to provide training opportunities for pulmonary and allergy fellows and other trainees in the design and implementation of clinical trials in a network setting. This proposal is leveraged on the complementary strengths on the Duke Asthma Center and the Arizona Respiratory Center in the areas of severe adult asthma and childhood asthma, respectively. The Duke Asthma Center has pioneered work in the cellular and molecular biology of asthma using invasive methods to obtain airway samples, whereas the Arizona Respiratory Center is a leader in the genetics and pharmacogenetics of asthma. Both teams have extensively participated in previous NHLBI-funded asthma networks, and they have access to large populations of both children and adults with asthma of a wide range of severities. These strategies, together with our demonstrated capacity to work effectively in collaborative environments, are unique contributions that the Duke/University of Arizona AsthmaNet Center can make to the AsthmaNet initiative.

亚利桑那州杜克大学哮喘中心包括两个临床管理试验方案建议。成人哮喘管理试验将评估TNF-Alpha拮抗剂在优化药物治疗和合并症治疗后保持控制的肥胖受试者中哮喘控制中的作用。小儿哮喘管理试验将检验以下假说：急性哮喘加重的首次症状可以使用大溶霉素，以防止这种加重，如果这种预防效果特异性是针对IL8/-159 aa的IL8/-159 aa的危险中的基因组中的基因型中的特异性，则该基因型的风险相关。恶化。我们还提出了两个简短的概念提案：一个我们将测试肥胖哮喘受试者的类固醇耐药性，第二个我们将确定霉菌性富含丙氨酸的激酶底物（MARCKS）相关的肽的效果，这是Mucus分泌的潜在调节剂，可改善Mucus Contrion contrimiation Contriming Contrictma。最后，我们提出了一项临床研究技能发展核心计划，该计划将使用我们两个临床研究单元中可用的许多临床，遗传和生物学和培训资源，以在网络环境中设计和实施临床试验时为肺和过敏研究员和其他受训者提供培训机会。 该提议分别在严重的成年哮喘和儿童哮喘的地区的杜克哮喘中心和亚利桑那呼吸中心的互补优势上杠杆作用。杜克哮喘中心使用侵入性方法在哮喘的细胞和分子生物学中开创了研究，以获取气道样品，而亚利桑那州呼吸中心是哮喘遗传学和药物遗传学的领导者。两支球队都广泛地参与了以前的NHLBI资助的哮喘网络，他们可以进入大量儿童和成人，患有广泛严重性的哮喘。这些策略，加上我们在协作环境中有效工作的能力，是亚利桑那州杜克大学哮喘中心可以对asthmanet倡议做出的独特贡献。